ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors
Phase 1 Completed
28 enrolled
Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer
Phase 1 Completed
23 enrolled 11 charts
MK-4830-001
Phase 1 Completed
470 enrolled
Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations
Phase 1 Completed
34 enrolled
Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors
Phase 1 Completed
446 enrolled 49 charts
TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers
Phase 1 Completed
56 enrolled 19 charts
Nilotinib in Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients With Stage I-III Breast Cancer
Phase 1 Completed
11 enrolled 9 charts
KETO-CARE
Phase 1 Completed
20 enrolled
T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer
Phase 1 Completed
20 enrolled
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer
Phase 1 Completed
48 enrolled
A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies
Phase 1 Completed
35 enrolled
A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer
Phase 1 Completed
139 enrolled
Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer
Phase 1 Completed
9 enrolled 17 charts
Testing the Addition of the Anti-Cancer Drug Talazoparib to the Combination of Carboplatin and Paclitaxel for the Treatment of Advanced Cancer
Phase 1 Completed
43 enrolled
Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer
Phase 1 Completed
50 enrolled
Selumetinib and Paclitaxel as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer
Phase 1 Completed
23 enrolled
TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
52 enrolled
Pembrolizumab and Paricalcitol With or Without Chemotherapy in Patients With Pancreatic Cancer That Can Be Removed by Surgery
Phase 1 Completed
9 enrolled
Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer
Phase 1 Completed
26 enrolled
Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer
Phase 1 Completed
38 enrolled
Sapanisertib, Carboplatin, and Paclitaxel in Treating Patients With Recurrent or Refractory Malignant Solid Tumors
Phase 1 Completed
35 enrolled
BYL719 in Combination With Gemcitabine and (Nab)-Paclitaxel in Locally Advanced and Metastatic Pancreatic Cancer
Phase 1 Completed
15 enrolled
Paclitaxel and Nortriptyline Hydrochloride in Treating Patients With Relapsed Small Cell Carcinoma
Phase 1 Completed
2 enrolled
Epi-PRIMED
Phase 1 Completed
8 enrolled
Ganetespib in Combination With Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-III Esophageal Cancer
Phase 1 Completed
3 enrolled
Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
Phase 1 Completed
113 enrolled
Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer)
Phase 1 Completed
40 enrolled
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
Phase 1 Completed
37 enrolled
Nab-paclitaxel (Abraxane) With or Without Mifepristone in Patients With Advanced Breast Cancer
Phase 1 Completed
9 enrolled
Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
Phase 1 Completed
9 enrolled
Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer
Phase 1 Completed
18 enrolled
Paricalcitol and Chemotherapy in Treating Women With Metastatic Breast Cancer
Phase 1 Completed
24 enrolled
Paclitaxel and Bavituximab in Treating Patients With HER2-Negative Metastatic Breast Cancer
Phase 1 Completed
14 enrolled
Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery
Phase 1 Completed
13 enrolled
Hepatic Arterial Infusion (HAI) of Abraxane
Phase 1 Completed
64 enrolled
Hepatic Arterial Infusion of Nab-Paclitaxel in Patients With Metastatic Melanoma in the Liver
Phase 1 Completed
30 enrolled
Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer
Phase 1 Completed
107 enrolled
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer
Phase 1 Completed
35 enrolled
Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma Cancer
Phase 1 Completed
43 enrolled
TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
Phase 1 Completed
20 enrolled
Temsirolimus, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
38 enrolled
Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors
Phase 1 Completed
18 enrolled
Bortezomib and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors
Phase 1 Completed
45 enrolled
Combination Chemotherapy Plus Oblimersen in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
55 enrolled
Vorinostat, Paclitaxel, and Carboplatin in Treating Patients With Advanced or Refractory Solid Tumors
Phase 1 Completed
30 enrolled
17-N-Allylamino-17-Demethoxygeldanamycin and Paclitaxel in Treating Patients With Metastatic or Unresectable Solid Tumor
Phase 1 Completed
35 enrolled
Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer
Phase 1 Completed
30 enrolled
Erlotinib, Trastuzumab, and Paclitaxel in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
40 enrolled
PS-341 and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
96 enrolled
Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Phase 1 Completed
36 enrolled